West Pharmaceutical Services, Inc. (WST): Business Model Canvas [June-2026 Updated]

This ready-made Business Model Canvas of West Pharmaceutical Services, Inc. gives you a clear, practical view of how the company creates value through high-value sterile components, integrated prefillable syringe systems, and contract manufacturing. You will see how key resources like HVP capacity, the Synchrony S1 PFS platform, NovaPure and FluroTec technologies, and global sites in the U.S., Ireland, and Germany support customers in biologics, vaccines, GLP-1, and other pharma segments, while direct sales, West Vantage, and technical teams drive delivery. It also breaks down the main revenue streams, cost drivers, and strategic partnerships, including AbbVie, giving you a solid study and research aid for coursework, essays, case studies, presentations, or business analysis projects.

West Pharmaceutical Services, Inc. - Canvas Business Model: Key Partnerships

$65 million was the disclosed cash value of West Pharmaceutical Services, Inc.'s SmartDose intellectual property sale to AbbVie in 2018.

Partner	Partnership type	What the partnership does	Real-life disclosed number	Business model impact
AbbVie	Strategic customer and IP transaction counterparty	SmartDose intellectual property sale tied to drug delivery technology and West's Tempe, Arizona site relationship	$65 million	Turns a drug delivery platform into cash, reduces direct product exposure, and keeps West tied to high-value pharmaceutical delivery programs
Biologics, vaccine, and GLP-1 pharma customers	Core commercial partnerships	Supply of containment and delivery components for injectable medicines	Not publicly disclosed by customer in this context	Drives recurring demand, especially where sterile packaging and self-injection systems are needed
Executive recruiting firm	Governance and succession support	CEO succession search support	Not publicly disclosed	Reduces leadership-transition risk and supports continuity in capital allocation and customer relationships
SBTi	Climate-target validation body	Validates emissions targets	Not a monetary transaction	Raises credibility with large pharma customers that require decarbonization progress from suppliers

AbbVie is the clearest example of a partnership that combines commercial scale with intellectual property monetization. West Pharmaceutical Services, Inc. sold SmartDose intellectual property to AbbVie for $65 million, which shows that partnerships can create value beyond recurring product sales. For a company like West, this matters because drug delivery systems are expensive to develop and can be converted into upfront cash when the strategic fit changes.

The Tempe, Arizona connection matters because it shows how West's partnership model is not only about selling components. It can also include site-linked technical work, manufacturing support, and asset transfer. In academic terms, this is a useful case of vertical specialization: West focuses on delivery systems and containment, while a partner like AbbVie focuses on branded therapeutics.

• $65 million cash consideration from the SmartDose IP sale to AbbVie
• Tempe, Arizona as the named site tied to the relationship
• Technology transfer rather than only product supply

Biologics customers are central because West's value creation depends on regulated sterile drug packaging, injection components, and delivery systems. Biologics usually require tighter containment and higher-performance materials than small-molecule drugs. That makes West's partnerships sticky: once a customer validates a component in an approved product, switching suppliers is slow, costly, and risky.

Vaccine customers add volume sensitivity. When vaccine production rises, West's packaging and delivery components can see stronger demand. GLP-1 pharma customers matter for a different reason: chronic injectable therapies create repeated use across a large patient base, so the supply relationship can be long-lived and operationally important. In business model terms, these partnerships support both unit demand and long-duration product qualification.

Customer group	Why the partnership matters	Main business model effect	Data point available
Biologics pharma customers	Need sterile, high-performance containment and delivery systems	Higher qualification barriers and stronger supplier retention	Not disclosed
Vaccine customers	Need reliable, regulated packaging at scale	Volume support during production cycles	Not disclosed
GLP-1 pharma customers	Need injection-compatible systems for repeated patient use	Supports recurring demand and platform breadth	Not disclosed

The executive recruiting firm partnership is a governance tool, not an operating supply chain link. A CEO succession search usually means the board wants outside help to identify candidates, screen experience, and manage transition risk. This matters for customers because pharmaceutical supply partnerships depend on trust, quality systems, and regulatory discipline, all of which can be disrupted by leadership turnover if the transition is weak.

For academic work, this is a strong example of how the Business Model Canvas includes non-operating partners. A recruiting firm does not make or sell West's products, but it helps preserve execution quality at the top of the organization. That makes it part of the support structure behind West's revenue model, capital allocation, and customer continuity.

• Board-level CEO succession support
• External candidate screening and transition planning
• Leadership continuity for regulated manufacturing and pharma customer retention

SBTi, the Science Based Targets initiative, matters because large pharmaceutical customers increasingly push suppliers to prove emissions reductions. Validation from SBTi gives West more credibility in customer qualification processes, supplier scorecards, and sustainability reporting. This is not a direct revenue partnership, but it can affect bid access, customer preference, and long-term contract defense.

In business model terms, validated emissions targets can lower commercial friction with procurement teams at biologics and vaccine customers. It also helps West show that its manufacturing footprint is moving in a direction that matches customer decarbonization goals. That is important in supply chains where ESG screening can affect vendor selection even when product performance is already approved.

Climate partner	Role	Commercial relevance	Number disclosed
SBTi	Validates emissions targets	Supports customer sustainability requirements and supplier qualification	Not monetary

$65 million is the only partnership-specific financial amount in the outline that is clearly tied to a disclosed transaction. The other partnerships matter because they protect recurring demand, reduce transition risk, and strengthen West Pharmaceutical Services, Inc.'s position inside highly regulated medicine supply chains.

West Pharmaceutical Services, Inc. - Canvas Business Model: Key Activities

West Pharmaceutical Services, Inc. builds its business around sterile packaging components, delivery systems, and contract services for injectable drugs and biologics. The core activities are manufacturing, systems development, quality control, regulatory compliance, and global capacity management.

Key activity	Business purpose	Why it matters financially
Manufacture high-value sterile components	Produce elastomer, polymer, and containment parts for injectable medicines	Supports recurring demand from pharmaceutical and biotechnology customers
Develop integrated prefillable syringe systems	Design delivery systems that combine components into a drug-contact solution	Raises switching costs and supports higher-value product sales
Expand contract manufacturing and kitting	Provide assembly, packaging, and custom kit preparation services	Adds service revenue and improves customer retention
Ensure quality, validation, and regulatory compliance	Meet pharmaceutical manufacturing and inspection standards	Reduces recall risk, plant disruption, and customer qualification barriers
Optimize global capacity and supply chain	Balance output, inventory, and delivery across sites and markets	Protects margins and service levels in a regulated supply chain

Manufacture high-value sterile components is the central activity in West Pharmaceutical Services, Inc.'s model. The company makes components used in injectable drug packaging and delivery, where contamination control and dimensional precision matter. These products are not generic industrial parts. They must meet tight specifications because they come into contact with medicines that are often high-cost and highly regulated. That makes manufacturing capability itself a strategic asset. When customers qualify a component for a drug product, they are not just buying a part. They are tying that part to a regulated medicine lifecycle.

This activity matters because sterile components support repeat orders over long product cycles. Once a component is validated in a drug application, changing suppliers can be costly and slow. That gives West Pharmaceutical Services, Inc. a stronger position than a low-spec supplier. The economics of the activity depend on yield, scrap rates, cleanroom performance, and process consistency. Small changes in these variables can affect output, margin, and customer service levels.

• Elastomer components for injectable packaging
• Polymer and containment products for drug storage and delivery
• High-specification parts that require controlled manufacturing environments
• Products tied to long customer qualification cycles

Develop integrated prefillable syringe systems is a higher-value activity because it shifts the company from making single parts to supplying a system. A syringe system can include multiple compatible components that must work together with the drug, the filling process, and the final delivery method. This is important for biologics and other injectable therapies where dose accuracy and contamination control are critical. The company's role here is not just manufacturing. It also includes design integration, testing, and support for pharmaceutical customers during development.

For strategy, this activity raises switching costs. If the syringe system is integrated into a customer's formulation and filling process, a competitor cannot replace it easily. That supports pricing power and helps West Pharmaceutical Services, Inc. protect revenue from commoditization. The activity also links closely to customer development timelines, so it creates early-stage involvement before commercial launch. In academic work, this is a good example of a company moving up the value chain from components to systems.

• Component integration
• Functional testing with drug-delivery requirements
• Customer collaboration during development and scale-up
• Support for injectable therapies that require prefillable formats

Expand contract manufacturing and kitting adds a services layer to the business model. Contract manufacturing means West Pharmaceutical Services, Inc. produces or assembles products for a customer under specification. Kitting means grouping separate items into packaged sets for later use. In pharmaceutical supply chains, that can reduce customer handling steps and simplify downstream operations. This activity is important because it can turn a component supplier into a broader operational partner.

The business impact is clear. Services can deepen customer relationships, increase share of wallet, and create more touchpoints in the supply chain. Kitting also makes West Pharmaceutical Services, Inc. more useful to customers that want finished, ready-to-use packs instead of loose parts. That can improve service differentiation even when underlying components are similar across suppliers. For an academic paper, this is a good case of how a manufacturer can add value through process design, not just physical production.

• Custom assembly for pharmaceutical customers
• Kit preparation for downstream use in manufacturing or clinical settings
• Operational support that reduces customer handling steps
• Higher service intensity than component-only sales

Ensure quality, validation, and regulatory compliance is one of the most important key activities in the entire business. West Pharmaceutical Services, Inc. operates in a sector where product failure can lead to drug contamination, recalls, or regulatory action. Validation means proving that a process or product works consistently within defined limits. Quality systems document that proof. Regulatory compliance means meeting the requirements of agencies and standards that govern pharmaceutical manufacturing.

This activity matters because the cost of failure is far higher than in ordinary manufacturing. A defect can interrupt a customer's drug supply or delay a launch. That can damage trust and create switching pressure. Strong compliance, on the other hand, supports customer confidence and helps the company win business from highly regulated drug makers. In strategic terms, quality is not just a control function. It is part of the product itself.

Quality-related focus	Operational effect
Validation	Shows that a process produces consistent output
Inspection and testing	Detects defects before shipment
Documentation control	Supports audit readiness and traceability
Regulatory compliance	Protects market access and customer approvals

Optimize global capacity and supply chain is the activity that connects manufacturing to delivery. West Pharmaceutical Services, Inc. has to balance capacity, inventory, transport, and lead times across a regulated international network. In sterile packaging, customers expect reliability, not just availability. A missed shipment can disrupt a drug production schedule. That means supply chain execution has direct financial consequences through service levels, customer retention, and working capital.

Capacity optimization also matters because pharmaceutical demand is uneven. Some products scale quickly, while others move slowly through development and approval stages. The company must match production capability to demand without carrying excessive inventory or running plants below efficient levels. In academic analysis, this is a useful example of how operations management affects margins. Efficient supply chains lower waste, improve throughput, and reduce stockouts, but they also need strong planning discipline and global coordination.

• Site-to-site production balancing
• Inventory planning for regulated components
• Transport coordination for temperature-sensitive and time-sensitive shipments
• Demand planning linked to customer launches and restocking cycles

The key activities also fit the company's broader economics. Sterile component manufacturing creates the base revenue engine. Integrated systems and contract services raise the average value of each customer relationship. Quality and validation protect the franchise. Capacity and supply chain work keep the business deliverable at scale. Together, these activities support a model built on technical expertise, regulatory trust, and repeated use in pharmaceutical production.

West Pharmaceutical Services, Inc. - Canvas Business Model: Key Resources

$2.893 billion in 2024 net sales shows the scale of the resource base behind West Pharmaceutical Services, Inc., but the real strategic value sits in its specialized manufacturing assets, proprietary technologies, and regulated global footprint.

HVP manufacturing capacity is a core resource because high-value products for injectable drugs depend on controlled, validated production. This capacity matters because it supports complex primary packaging and drug-delivery components that customers cannot switch quickly. In practical terms, this kind of asset is not just plant space; it is qualified equipment, cleanroom control, process validation, and customer-approved production lines that are hard to replicate.

Synchrony S1 PFS platform is a resource because it supports prefilled syringe programs that reduce handling steps and improve usability in injectable drug delivery. For West, the value of this platform is not only the product itself but the technical know-how, design history, and customer integration around it. That makes it a platform resource, not a single product resource.

NovaPure and FluroTec are proprietary technology resources because they support product differentiation in containment and drug-contact performance. In a business model canvas, proprietary technologies matter because they strengthen pricing power, customer stickiness, and regulatory defensibility. They are also important in academic analysis because they show how intellectual property and process know-how can be more valuable than physical plant alone.

West Vantage is a contract manufacturing resource because it expands West Pharmaceutical Services, Inc.'s ability to produce under customer specifications while staying inside a highly regulated environment. This matters strategically because contract manufacturing creates recurring demand for qualified capacity, technical service, and validated production support.

Global facilities in the U.S., Ireland, and Germany are a key resource because geographic dispersion supports customer service, supply continuity, and regulatory resilience. For injectable drug components and delivery systems, location matters because customers need reliable supply, shorter lead times, and backup capacity. A multi-country footprint also reduces dependence on a single site and helps the company serve multinational pharmaceutical customers.

Key resource	Real-life number or amount	Business meaning
2024 net sales	$2.893 billion	Shows the scale that supports capital-intensive manufacturing and proprietary platforms

• HVP manufacturing capacity supports high-value injectable components and customer-qualified production.
• Synchrony S1 PFS platform supports prefilled syringe delivery programs.
• NovaPure supports container closure performance and product differentiation.
• FluroTec supports drug-contact performance and customer retention.
• West Vantage supports contract manufacturing under validated operating conditions.
• U.S., Ireland, and Germany facilities support supply continuity and geographic redundancy.

In Business Model Canvas terms, these resources are the assets West uses to create value through controlled manufacturing, technical reliability, and regulated product performance. They also shape the company's ability to capture value because customers in pharmaceutical packaging and delivery systems pay for qualification, consistency, and supply assurance rather than for low-cost commodity production.

West Pharmaceutical Services, Inc. - Canvas Business Model: Value Propositions

West Pharmaceutical Services, Inc. is built around a value proposition that combines integrated injectable drug packaging systems, sterile components, and manufacturing reliability. The company has operated since 1923 and reports through 2 business segments: Proprietary Products and Contract-Manufactured Products.

Its value is strongest where drug makers need fewer supplier handoffs, tighter container-control performance, and sterile packaging that supports regulated manufacturing and launch timelines. That matters most in biologics, high-volume injectable programs, and products that require supply continuity.

Value proposition	Direct business impact	Why customers pay for it
Integrated systems shorten client development timelines	Combines components and packaging systems into a single development path	Fewer vendor interfaces, faster qualification work, and less project friction
High-performance components reduce container interaction	Supports product integrity in injectable formats	Lower risk of drug-container issues during storage and use
Sterile HVP products support regulatory compliance	Provides sterile, ready-to-use supply for regulated markets	Less internal sterilization burden and smoother validation work
Scalable capacity for biologics and GLP-1 demand	Supports higher-volume demand in injectable growth categories	Customers need repeatable supply for launches and expansion
Onshored U.S. manufacturing supports supply assurance	Reduces dependency on long, complex offshore supply chains	Customers want continuity, shorter logistics paths, and lower disruption risk

Integrated systems shorten client development timelines because West Pharmaceutical Services, Inc. sells more than isolated parts. In injectable drug packaging, a customer often needs a closure, container system, and compatibility testing to work together. When one supplier can support that path, the customer spends less time coordinating development work. That matters in academic analysis because time-to-market is a competitive variable, not just an operational detail.

• Fewer suppliers mean fewer handoffs in development.
• Fewer handoffs can reduce rework during qualification.
• Shorter development cycles matter more in biologics than in simple dosage forms.

High-performance components reduce container interaction by lowering the chance that the packaging system affects the drug. In injectable products, container interaction can affect stability, sterility, and usability. West Pharmaceutical Services, Inc. competes on performance at the component level, which is valuable when the medicine is sensitive and the margin for error is small.

This proposition is especially important for products stored for long periods or delivered in precision-controlled formats. For students writing about the Business Model Canvas, this shows how a company creates value through product quality, not just price.

• Container interaction risk is a packaging quality issue.
• Quality problems can create delays, recalls, or reformulation work.
• Customers value performance because failures are costly.

Sterile HVP products support regulatory compliance because sterile supply reduces a customer's own processing burden. In regulated pharmaceutical manufacturing, sterility control and validation add cost and complexity. West Pharmaceutical Services, Inc. fits into that need by offering products that are designed for sterile, high-value injectable use.

The business value is straightforward: customers can reduce internal steps, simplify quality documentation, and support compliance expectations across manufacturing and distribution. That makes the proposition strong in academic discussion of regulated industries, where compliance capability is part of the product, not a separate feature.

Scalable capacity for biologics and GLP-1 demand matters because injectable demand is not evenly distributed. When demand rises quickly in biologics or GLP-1-related programs, customers need suppliers that can grow output without breaking supply continuity. West Pharmaceutical Services, Inc. benefits when customers want a partner that can support higher-volume production and repeat orders.

The strategic value here is capacity plus reliability. In business model terms, capacity is part of the offer because it protects the customer's launch plan and ongoing supply. For research and case work, this is a useful example of how operations become part of value creation.

• Biologics usually require tighter packaging controls than many traditional drugs.
• High-volume injectable demand makes supplier scale more important.
• Capacity is valuable when shortages can disrupt patient access.

Onshored U.S. manufacturing supports supply assurance because domestic production can reduce exposure to cross-border delays and geopolitical disruption. For customers, the value is not only proximity. It is also control, predictability, and faster response if demand changes. In regulated supply chains, those factors can be as important as unit cost.

West Pharmaceutical Services, Inc. uses U.S. manufacturing as part of its promise to supply critical components with greater continuity. That is important in academic work on sourcing strategy because onshoring is a response to concentration risk, transportation risk, and quality-control risk.

Value proposition driver	Customer problem solved	Strategic relevance
Integrated systems	Too many suppliers and too much coordination	Speeds development and reduces friction
Low-interaction components	Packaging that can affect drug quality	Supports product performance and trust
Sterile HVP products	Validation and compliance burden	Fits regulated manufacturing requirements
Scalable capacity	Growth in biologics and GLP-1 demand	Supports launch and expansion plans
Onshored U.S. manufacturing	Supply-chain disruption risk	Improves continuity and responsiveness

• 1923 marks the company's long operating history, which supports buyer confidence in regulated markets.
• 2 reporting segments show a split between proprietary and contract manufacturing activity.
• The value proposition centers on injectable drug packaging, not generic packaging.
• Customer value comes from development speed, compliance support, and supply assurance.

West Pharmaceutical Services, Inc. - Canvas Business Model: Customer Relationships

West Pharmaceutical Services, Inc. builds customer relationships through long-term B2B supply contracts, technical support for validation and design, contract manufacturing agreements, custom component support, and ongoing quality and traceability services.

Customer relationship type	What it looks like in practice	Why it matters to the customer	Why it matters to Company Name
Long-term B2B supply relationships	Recurring supply of components and packaging systems for injectable drugs	Stable sourcing, lower supply risk, and fewer production disruptions	Repeat demand, higher switching costs, and long customer retention
Technical collaboration on validation and design	Joint work on container-closure systems, extractables and leachables, and product fit	Faster product development and better regulatory readiness	Deeper integration into customer programs and stronger account lock-in
Contract manufacturing service agreements	Agreements tied to defined production, quality, and delivery requirements	Capacity access and predictable supply	Contracted revenue and multi-year customer ties
Custom component development support	Tailored elastomer, polymer, and delivery-system components	Better compatibility with drug formulation and device design	Higher-value relationships and differentiation versus standard catalog supply
Ongoing quality and traceability support	Batch traceability, quality documentation, and change-control support	Audit readiness and supply-chain visibility	Lower churn risk and stronger compliance-based customer dependence

Long-term B2B supply relationships are the core of Company Name's customer model. The company serves pharmaceutical, biotechnology, and generic-drug manufacturers that need injectable packaging and containment components over many production cycles. These relationships are usually sticky because changing a component supplier can trigger revalidation, new testing, and regulatory documentation updates. In this market, the customer relationship is not just a sales transaction; it is part of the customer's regulated manufacturing process.

For academic work, this matters because the relationship creates a structural moat. The customer is not buying a single part. The customer is buying continuity, validated performance, and supply reliability across a product lifecycle that can last years.

• High switching costs from requalification and regulatory review
• Recurring demand from approved drug and device programs
• Account relationships that often run across multiple product lines and facilities

Technical collaboration on validation and design is a central relationship layer. Company Name works with customers during product development, compatibility testing, and manufacturing validation. In injectable drug packaging, validation means proving that a component performs as expected under real manufacturing and storage conditions. Design support often covers dimensional fit, material choice, and performance under sterilization or filling conditions.

This relationship reduces customer risk because the wrong packaging component can affect product integrity, shelf life, or regulatory acceptance. It also raises the value of Company Name's role from supplier to technical partner. That makes the relationship more durable and less price-driven.

Technical support area	Customer need	Relationship effect
Validation support	Proof that the component works in the intended drug process	Longer engagement cycle and stronger dependence on Company Name
Design collaboration	Fit between component and delivery system	More customized specifications and higher barriers to substitution
Compatibility testing	Material interaction with drug formulation	Better customer confidence and lower launch risk

Contract manufacturing service agreements create another relationship type that is more formal and more operationally embedded. In this model, Company Name is not only supplying parts but also providing manufacturing services under defined terms. The customer depends on the company for quality, capacity, and delivery consistency. That makes the relationship contractual, process-driven, and often long term.

These agreements matter because they support predictable supply in a regulated market where disruptions can delay drug launches or commercial production. For Company Name, they support recurring business and deepen operational integration with the customer's supply chain.

• Defined production volumes and quality requirements
• Structured delivery schedules
• Formal service-level expectations
• Shared responsibility for manufacturing continuity

Custom component development support is a relationship built around tailored solutions rather than standard products. Customers often need components designed for a specific biologic, syringe, vial, cartridge, or delivery system. That can involve material selection, coating performance, dimensional tolerances, and compatibility with filling and sterilization processes. Company Name's relationship becomes more valuable when it helps a customer move from concept to commercial launch.

This is important in an academic analysis because customization increases customer lock-in. When a component is built around a specific formulation or device, replacing it later is harder and more expensive. The relationship therefore supports pricing power and long-term retention, even without publicly disclosed contract values.

Ongoing quality and traceability support is essential in pharmaceutical supply relationships. Customers need batch-level traceability, quality records, change-control communication, and documentation that supports audits and inspections. This is especially relevant in regulated manufacturing environments covered by standards such as 21 CFR Parts 210, 211, and 820 and packaging-related quality systems such as ISO 15378.

Quality support affects customer relationships because it reduces compliance risk. Traceability helps customers identify affected lots quickly if a defect, deviation, or recall issue occurs. That makes Company Name more than a vendor. It becomes part of the customer's risk-management process.

Quality and traceability element	Customer use	Strategic impact on Company Name
Batch traceability	Lot identification and root-cause analysis	Higher trust and lower relationship churn
Quality documentation	Audit and regulatory support	Stronger integration into customer compliance workflows
Change-control communication	Assessment of supplier or process changes	Longer approval cycles that favor established suppliers
Deviation support	Response to manufacturing or quality issues	Reinforces dependence on a proven partner

The relationship model is built for B2B customers with high regulatory exposure, long product cycles, and low tolerance for supply failure. That makes it very different from consumer-oriented relationship models. In Company Name's case, the customer relationship is less about marketing and more about technical reliability, compliance, and uninterrupted supply.

The practical result is a relationship structure that typically rewards long tenure, repeated qualification, and cross-functional support across procurement, engineering, quality, and regulatory teams.

West Pharmaceutical Services, Inc. - Canvas Business Model: Channels

$2.89 billion in 2024 net sales is the latest full-year companywide sales figure that frames how West Pharmaceutical Services, Inc. reaches customers through direct commercial coverage, contract manufacturing, global production, industry events, and technical support.

Channel	What it does	Real-life numbers tied to the channel
Direct sales teams	Commercial coverage for pharmaceutical and biotech accounts	$2.89 billion net sales in 2024
West Vantage contract manufacturing platform	Custom manufacturing and fill-finish related customer access point	1 named contract manufacturing platform
Global manufacturing sites	Local supply, production resilience, and customer proximity	25 manufacturing sites worldwide
Industry launches and trade events	Product visibility and customer lead generation	1 channel type used across global life sciences events
Customer technical and validation teams	Specification support, testing, and implementation help	1 technical support channel tied to qualification and validation

Direct sales teams are the main commercial channel for West Pharmaceutical Services, Inc. because the company sells into regulated drug-delivery and packaging workflows that usually require long account cycles, qualification work, and recurring technical contact. The company's 2024 net sales were $2.89 billion, which shows the scale that direct account coverage must support across pharmaceutical and biotech customers.

Direct sales matters because each customer decision can affect product specifications, device compatibility, drug-container interaction, and long-term supply agreements. In this type of business, one account team often covers multiple functions inside a customer organization, including procurement, engineering, quality, and manufacturing.

• $2.89 billion net sales in 2024 supports a large direct-selling structure.
• Direct coverage is important for regulated products with qualification and validation requirements.
• Commercial work is tied to recurring customer programs, not one-time retail transactions.

West Vantage contract manufacturing platform is a dedicated channel for customers that need outsourced manufacturing support rather than only standalone components. The platform gives West a way to capture more of the production value chain by combining product design, manufacturing, and customer-specific program support under a single access point.

This channel matters because contract manufacturing typically deepens customer dependence and increases switching costs. Once a drug program is validated on a specific process, changing suppliers can require revalidation work, new documentation, and quality review. That makes West Vantage more than a sales line; it is a customer retention channel.

• 1 named contract manufacturing platform: West Vantage.
• Qualification and revalidation create switching costs for customers.
• The platform supports more integrated customer relationships than component-only sales.

Global manufacturing sites are a channel because they are the physical delivery points that connect West's commercial commitments to customer supply. West reported 25 manufacturing sites worldwide, which gives the company a broad footprint for production, regional supply, and business continuity.

For a medical packaging and delivery systems business, site geography affects lead times, freight costs, customer qualification, and supply risk. A multi-site network can help customers reduce concentration risk, especially when they operate global drug supply chains that need consistent quality and available inventory.

Global footprint measure	Number	Channel impact
Manufacturing sites	25	Regional supply, customer proximity, continuity
Net sales	$2.89 billion	Scale needed to support a global delivery network

Industry launches and trade events support the channel by exposing West's products, technology platforms, and customer capabilities to pharmaceutical executives, engineers, and procurement teams. In this market, launches are not just marketing events; they are part of the customer acquisition process because many customers need to see performance data, compatibility information, and use-case evidence before adoption.

Trade events matter because they compress sales cycles by putting technical and commercial teams in front of multiple decision-makers at once. For a company with $2.89 billion in annual sales, event-based access is useful for pipeline generation, new program discussions, and cross-selling into existing accounts.

• Trade events support pipeline development across large pharmaceutical accounts.
• Launch activity helps explain product performance before customer qualification begins.
• Event coverage works best when paired with direct sales and technical follow-up.

Customer technical and validation teams are one of the most important channels in West Pharmaceutical Services, Inc. because many products must pass customer testing before they can be used in commercial drug programs. Validation work often includes material testing, compatibility review, process qualification, and quality documentation.

This channel matters because technical approval is often the gate between a product demonstration and a commercial order. In regulated healthcare supply chains, the customer's validation team can slow or accelerate adoption depending on whether the product meets specification, documentation, and manufacturing requirements.

• Validation is part of the buying process, not a post-sale activity.
• Technical support helps customers qualify products for regulated use.
• Customer approval can determine whether a program becomes recurring revenue.

West Pharmaceutical Services, Inc. - Canvas Business Model: Customer Segments

West Pharmaceutical Services, Inc. sells into five customer groups that all need sterile, high-integrity packaging or delivery components for injectable medicines. The common thread is scale, regulatory pressure, and low tolerance for contamination, which makes component reliability a buying criterion, not a nice-to-have.

Customer segment	Core need	What West typically supports	Why the segment matters
Biologics manufacturers	Sterile containment for sensitive large-molecule drugs	Containment and delivery components for injectables	Biologics often need tighter control over extractables, leachables, and container integrity
GLP-1 and non-GLP-1 drug makers	High-volume supply for chronic-care injectable therapies	Packaging and delivery components for pens, syringes, and vials	High-volume launches can drive recurring demand and qualification lock-in
Vaccine manufacturers	Reliable packaging for large public-health supply chains	Components for sterile primary packaging systems	Demand can spike with immunization campaigns and pandemic response
Combination product companies	Drug-device compatibility and regulatory documentation	Integrated component systems for combination products	Device compatibility raises switching costs once a design is approved
Pharmaceutical firms onshoring to North America	Shorter supply chains and domestic sourcing	North America-based supply support and manufacturing	Onshoring reduces geopolitical and logistics risk for buyers

Biologics manufacturers are one of West's most important customer groups because biologics are structurally harder to package than small-molecule drugs. These medicines are often more sensitive to heat, light, and contamination, so the customer needs tighter quality control and more validated materials. For academic work, this segment matters because it shows why West's business is tied to the growth of injectable biologics, not just generic packaging demand. A biologics customer usually values supplier continuity, regulatory support, and qualification history more than low unit cost.

GLP-1 and non-GLP-1 drug makers represent a large injectable demand pool because obesity, diabetes, and chronic metabolic disease therapies are often delivered by pen, syringe, or vial. GLP-1 therapy created a second layer of demand on top of traditional injectable pipelines. Non-GLP-1 therapies still matter because West's customer base is not dependent on one therapeutic class. The commercial logic is simple: if a drug is launched at scale and uses sterile packaging, the component supplier can benefit for the full product life cycle, not just the launch quarter.

• GLP-1 makers need high-volume component supply.
• Non-GLP-1 injectable makers need the same regulatory and quality standards.
• Both groups often require long qualification cycles before commercial supply starts.

Vaccine manufacturers need West because vaccines are high-volume, time-sensitive products that depend on sterile packaging integrity. Vaccine demand is tied to immunization schedules, booster campaigns, and public-health response. That makes this segment less predictable than chronic-care drugs, but it can be extremely important when volume rises quickly. In business model analysis, this segment shows how West can benefit from both steady-state demand and event-driven demand. It also explains why supply resilience and manufacturing consistency matter so much in vaccine supply chains.

Combination product companies are customers that combine a drug with a device, such as an injector or delivery system. These buyers care about design compatibility, usability, and regulatory documentation because the drug and the device are reviewed together. Once a combination product is approved, switching components is difficult because the approved configuration becomes part of the regulatory file. That creates stickier customer relationships and raises the cost of supplier change. For West, this segment is strategically valuable because it supports longer product lifecycles and deeper integration into the customer's development process.

• Combination products create higher switching costs after approval.
• They require more technical support than standard packaging buyers.
• They often involve longer development timelines before commercial sales.

Pharmaceutical firms onshoring to North America are an important customer segment because supply chain security has become a purchase criterion. Buyers want domestic or regional sourcing to reduce lead times, freight exposure, and cross-border disruption. This matters more when the product is sterile, time-sensitive, or high value per dose. Onshoring also supports faster quality oversight and closer customer-vendor coordination. For academic analysis, this segment shows how West's customer base is shaped not only by medicine type, but also by manufacturing geography and supply chain strategy.

Segment driver	Customer purchasing logic	Effect on West
Biologic complexity	Need for validated sterile packaging	Higher value per qualification cycle
GLP-1 scale	Need for high-volume injectable supply	Recurring demand from large launch volumes
Vaccine urgency	Need for dependable public-health supply	Potential for sharp demand spikes
Combination product regulation	Need for integrated drug-device compatibility	Higher switching costs and longer customer retention
North America onshoring	Need for supply chain resilience	More demand for regional manufacturing support

West's customer segments are not isolated. A single pharmaceutical company can sit in more than one group, such as a biologics maker that also launches a combination product or an onshoring buyer that also needs chronic-care injectable packaging. That overlap matters because it increases the chance of cross-selling and long-term supply agreements. It also means West's revenue mix is shaped by therapeutic category, device format, and manufacturing location at the same time.

West Pharmaceutical Services, Inc. - Canvas Business Model: Cost Structure

$2,944.9 million net sales in 2023

Cost structure item	Real-life disclosed amount
Research and development	$63.0 million
Selling, general, and administrative	$325.4 million
Cost of sales	$2,077.8 million
Gross profit	$867.1 million

$63.0 million research and development expense in 2023

$2,077.8 million cost of sales in 2023

$867.1 million gross profit in 2023

• $2,077.8 million manufacturing, labor, materials, and plant overhead inside cost of sales
• $63.0 million R&D and product verification expense
• $325.4 million selling, general, and administrative expense tied to regulatory, quality, and validation work
• $0 separately disclosed legal and litigation expense line item in the 2023 income statement

$63.0 million R&D sits below the scale of $2,077.8 million cost of sales, showing that West Pharmaceutical Services, Inc. spends far more on making and supplying products than on pure research.

$2,077.8 million cost of sales covers manufacturing labor and materials. For a company like West Pharmaceutical Services, Inc., this is the core operating cost because the business sells high-specification components and containment systems that need controlled production, inspection, and batch consistency.

$63.0 million R&D expense is the clearest disclosed number for product development, testing, and product verification. This matters because West Pharmaceutical Services, Inc. must fund design validation, customer qualification, and compatibility testing before products can scale into regulated healthcare use.

$325.4 million SG&A includes the spending base that supports regulatory, quality, and validation work. In a regulated manufacturing business, these costs matter because they protect product approval status, customer confidence, and plant operating continuity.

$867.1 million gross profit shows the amount left after direct production costs. That spread is what pays for R&D, quality systems, compliance, sales support, corporate overhead, and legal exposure.

• $2,944.9 million net sales
• $2,077.8 million cost of sales
• $867.1 million gross profit
• $63.0 million R&D
• $325.4 million SG&A

$0 separately disclosed legal and litigation expense line item means legal cost is not presented as a stand-alone operating expense on the face of the 2023 income statement.

West Pharmaceutical Services, Inc. - Canvas Business Model: Revenue Streams

Proprietary Products and Contract-Manufactured Products are the two reported revenue sources. Proprietary Products includes High-Value Products and Standard Products, so most of the revenue logic sits inside one operating segment structure.

Revenue stream	Product or service base	Revenue character	Business model effect
Proprietary Products sales	High-Value Products and Standard Products	Product sales	Higher-margin mix depends on drug packaging and delivery demand
High-Value Products component sales	Components for injectable drug containment and delivery systems	Product sales	Supports recurring demand from pharma customers with regulated specifications
Contract manufacturing and kitting revenue	Made-to-order manufacturing and assembled kits	Service-linked manufacturing revenue	More customer-specific, usually tied to supply agreements and production volumes
Prefillable syringe system sales	Drug delivery system components and assemblies	Product sales within High-Value Products	Linked to injectable biologics and vaccine delivery formats
Standard Products sales	Commodity and general-use packaging and delivery components	Product sales	Typically lower differentiation than High-Value Products

Proprietary Products sales are the core revenue stream. This category includes products West designs and sells under its own specifications, which matters because it gives the company more pricing power than simple distribution or resale models. In practice, this stream is tied to injectable drug packaging, containment, and delivery formats used by pharmaceutical and biotechnology customers.

High-Value Products component sales are the most strategically important part of the revenue base. These products are built for regulated drug packaging and delivery use cases, so customers care about quality, consistency, and validation as much as unit price. That makes the revenue stream more durable than commodity supply, because switching costs are higher when components are embedded in approved drug supply chains.

Prefillable syringe system sales sit inside High-Value Products and connect directly to injectable drug delivery. This stream matters because prefillable systems are used where dosage accuracy, ease of use, and sterile packaging are critical. It links West's revenue to biologics, specialty medicines, and other injectable therapies where the packaging system is part of the finished medicine workflow.

• High-Value Products are more differentiated than Standard Products.
• Demand is tied to drug development, launch timing, and commercial manufacturing volumes.
• Customer qualification requirements can lengthen sales cycles but support longer relationships.
• Revenue quality is usually stronger when the product is embedded in regulated applications.

Contract manufacturing and kitting revenue comes from producing customer-specific items and assembling product kits. This stream is important because it broadens West beyond component sales and into a more integrated supply role. Kitting adds operational complexity, but it can deepen customer dependence and increase switching costs when the customer uses West as part of a controlled supply chain.

Standard Products sales are the more commodity-like part of Proprietary Products. These items usually face more price pressure and less product differentiation than High-Value Products. This matters for academic analysis because it creates a mix effect: as the share of High-Value Products rises, the revenue profile can become less exposed to commodity pricing and more exposed to regulated pharma demand.

• Standard Products are more exposed to price competition.
• They can still support volume stability when customers need baseline packaging supply.
• The mix between Standard Products and High-Value Products affects gross margin.
• A higher High-Value Products mix usually improves revenue quality.

West's revenue streams are concentrated in injectable drug packaging and delivery, so the business depends on the volume of biologics, sterile injectables, and other regulated therapies moving through customer production lines. That concentration matters because it links revenue to pharmaceutical production cycles, product approvals, and long-term supply relationships rather than broad consumer demand.

Revenue stream	Typical customer driver	Why it matters financially
Proprietary Products sales	Pharma and biotech demand for specialized components	Supports differentiated sales and pricing power
High-Value Products component sales	Injectable drug containment and delivery requirements	Usually stronger margin profile than Standard Products
Contract manufacturing and kitting revenue	Customer outsourcing of manufacturing and assembly	Expands revenue depth and customer stickiness
Prefillable syringe system sales	Demand for ready-to-use injectable delivery formats	Links revenue to biologics and specialty injectable growth
Standard Products sales	Baseline packaging and delivery needs	More exposed to pricing pressure and product substitution

Revenue recognition for these streams is tied to product shipment, delivery, or completed service activity under customer arrangements. For academic work, that means West's top line is not built on one-time licensing income or consumer-style repeat purchases. It is built on industrial and regulated supply relationships where volumes, specifications, and approval status shape the revenue base.